David Canes, MD
Urology · Burlington, MANPI 1841246576
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,550 of the $5,277 with a category attached, or 86.2%. Progenics Pharmaceuticals, Inc. accounts for 87.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $4,601 and has fallen 95.5% since, to $206 in 2025.
Across 29 payments — averaging $181.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Progenics Pharmaceuticals, Inc.$5K
- AbbVie$204
- Johnson & Johnson$110
- Sumitomo Pharma America, Inc.$63
- Procept Biorobotics Corporation$57
- Pfizer$36
- plus $187 from 8 others
Across 4 payments — averaging $2112.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intuitive Surgical Operations, Inc.$8K
What the payments were for
- Speaking & faculty fees$4,55086%
- Food & beverage$71213%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Progenics Pharmaceuticals, Inc. | 4 | $4,619 |
| AbbVie(2 entities) | 7 | $204 |
| Johnson & Johnson | 3 | $110 |
| Sumitomo Pharma America, Inc. | 3 | $63 |
| Procept Biorobotics Corporation | 1 | $57 |
| Pfizer | 2 | $36 |
| Ambu Inc. | 1 | $34 |
| Urogen Pharma, Inc. | 1 | $34 |
| Myriad Genetic Laboratories, Inc. | 2 | $28 |
| Telix Pharmaceuticals | 1 | $22 |
| BD | 1 | $20 |
| Civco Medical Instruments | 1 | $19 |
| Tolmar, Inc. | 1 | $18 |
| Smith+Nephew | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PYLARIFY$4,550
How this compares
$5,277 in reported general payments places this provider in the 70th percentile of 327 urology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 154 | $2,243 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 21 | $358 |
| Finasteride | 17 | $162 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $96 |
Paid to pharmacies, not to this prescriber.
Other urology in Burlington
- Michael CallegariBurlington$53K
- Peris CastanedaBurlington$51K
- Arthur MourtzinosBurlington$43K
- William du CombBurlington$9K
- Christopher CutieBoston$3.5M
- Brian EisnerBoston$424K
- David StaskinBrighton$407K
- Liam HurleyNorth Andover$319K
- Stephen DretlerBoston$298K
- Abraham MorgentalerChestnut Hill$290K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.